Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01601821
First received: May 3, 2012
Last updated: April 29, 2013
Last verified: April 2013
  Purpose

To compare the safety and efficacy of cyclosporine (CsA) + mycophenolate mofetil (MMF) + corticosteroids © to CsA + Rapamune + Cs with CsA elimination in the Rapamune arm with the introduction of MMF in de novo renal allograft recipients.


Condition Intervention Phase
Inflammation
Drug: CsA+Rapamune+CS
Drug: CsA+MMF+CS
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids With Further CSA Elimination In The Rapamune Arm With The Introduction Of MMF

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Incidence of Efficacy Failure [ Time Frame: Baseline up to Month 12 ] [ Designated as safety issue: No ]
    Efficacy failure was defined as first occurrence of either biopsy confirmed acute rejection, graft loss or death within 12 months of post-transplantation. Percentage of participants with efficacy failure was reported.


Secondary Outcome Measures:
  • Serum Creatinine Level [ Time Frame: Month 3, 6, 12 ] [ Designated as safety issue: No ]
    Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. An increased level of creatinine in the blood indicates decreased kidney function. Normal adult blood levels of creatinine are 0.5 to 1.1 milligram per deciliter (mg/dL) for females and 0.6 to 1.2 mg/dL for males; however, the normal values are age-dependent as elderly patients typically have smaller muscle mass.

  • Creatinine Clearance [ Time Frame: Month 3, 6, 12 ] [ Designated as safety issue: No ]
    Creatinine clearance (CCr) is a measure of kidney function. CCr is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Normal values for healthy, young males are in the range of 100-135 millimeters per minute (mL/min) and for females, 90-125 mL/min. Creatinine clearance decreases with age. A low creatinine clearance rate indicates poor kidney function.

  • Glomerular Filtration Rate (GFR) by Nankivell Method [ Time Frame: Month 3, 6, 12 ] [ Designated as safety issue: No ]
    GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR was calculated using the Nankivell formula. GFR by Nankivell equation= (6.7 per serum creatinine) plus (0.25*body weight) minus (0.5*serum urea) minus (100 per height square) plus (35 for male or 25 for female). A normal GFR is greater than (>)90 mL/min per 1.73 m^2 [mL/min/1.73 m^2], although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR less than (<)15 mL/min/1.73 m^2 indicated kidney failure.

  • Incidence of Biopsy-Confirmed Acute Rejection [ Time Frame: Baseline up to Month 6 ] [ Designated as safety issue: No ]
    Diagnosis of acute rejection was made via kidney biopsy using Banff criteria. Percentage of participants with biopsy-confirmed acute rejection was reported.

  • Histologic Grade of First Acute Rejection [ Time Frame: Baseline up to Month 12 ] [ Designated as safety issue: No ]
    Diagnosis of acute rejection was made via kidney biopsy. Categorization of biopsies with suspected acute rejection was based on histological findings using updated 1997 Banff criteria. Grade 1A: cases with significant interstitial infiltration (>25% of parenchyma affected) and foci of moderate tubulitis (5-10 cells/tubular cross section), Grade 1B: with severe tubulitis (>10 cells/tubular cross section), Grade 2A: mild-moderate intimal arteritis, Grade 2B: severe intimal arteritis and Grade 3: transmural arterits and/or fibrinoid necrosis. Data is reported as percentage of participants.

  • Percentage of Participants Who Survived [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    Survival defined as participants living with or without a functioning graft.

  • Percentage of Participants With Graft Survival [ Time Frame: Month 12 ] [ Designated as safety issue: Yes ]
    Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for >8 weeks), retransplant or death during the first 12 months after randomization.

  • Incidence of Presumptive or Documented Infection [ Time Frame: Baseline up to Month 12 ] [ Designated as safety issue: No ]
    Presumptive or documented infection during the 12 months after transplantation; was confirmed by culture, biopsy, or serology and reported. Percentage of participants with presumptive or documented infection was reported.

  • Incidence of Histologically Confirmed Lymphoproliferative Disease [ Time Frame: Baseline up to Month 12 ] [ Designated as safety issue: No ]
    Lymphoproliferative disorder represents an abnormal proliferation of B cells in response to either primary or reactivated infection with Epstein-Barr virus. Percentage of participants with histologically confirmed lymphoproliferative disease was reported.

  • Percentage of Participants With Efficacy Failure or Premature Elimination [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    Efficacy failure was defined as the first occurrence of acute rejection, graft loss, or death. Premature elimination was defined as elimination from the study for any other reason.

  • Incidence of Anemia [ Time Frame: Baseline up to Month 12 ] [ Designated as safety issue: No ]
    Diagnostic criterion for anemia was based on the laboratory results; in men: hemoglobin (Hb) <14 gram per deciliter (g/dL), hematocrit (Hct) <42%, or red blood cells (RBCs) <4.5 million/liter (million/L); for women: Hb <12 g/dL, Hct <37%, or RBC < 4 million/L. Percentage of participants with anaemia was reported.

  • Number of Participants Who Discontinued [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    Number of participants who discontinued the study treatment due to any reason is reported.


Enrollment: 245
Study Start Date: April 2006
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm A (CsA+Rapamune+CS) Drug: CsA+Rapamune+CS
Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months
Experimental: Arm B (CsA+MMF+CS) Drug: CsA+MMF+CS

The control arm is the standard local practice (official protocol) in Iran:

Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS.


  Eligibility

Ages Eligible for Study:   13 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 13 years and weight 40 kg
  • End-stage renal disease, with patients receiving a primary or secondary renal allograft from a living-unrelated donor, or from a living-related donor.
  • Women who are of childbearing potential must have a negative pregnancy test before enrollment in the study and agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months following discontinuation from the study.
  • Total white blood cell count 4.0 x 109/L (4,000/mmP3P), platelet count 100 x 10P9P/L(100,000/mmP3P), fasting triglycerides ≤ 4.6 mmol/L (400 mg/dL), fasting cholesterol ≤ 7.8 mmol/L (300 mg/dL). If it is not possible to obtain fasting triglycerides and cholesterol before surgery, historical values (within 1 year) may be used.
  • Signed and dated informed consent (parent or legal guardian must provide consent for patients <18 years of age). An assent form will be signed by patients < 18 years of age enrolled in the study.

Exclusion Criteria:

  • Evidence of active systemic or localized major infection at the time of initial Sirolimus administration.
  • Cadaveric donors
  • History of malignancy within 5 years before enrollment into the study (with the exception of adequately treated basal cell or squamous cell carcinoma of the skin)
  • Use of any investigational drug other than specified in the protocol during the 4 weeks before enrolling in the study.
  • Use of planned antibody induction therapy at the time of transplantation.
  • Active gastrointestinal disorder that may interfere with drug absorption.
  • Known hypersensitivity to Sirolimus, MMF or Cyclosporine or its derivatives.
  • Multiple organ transplants (2 or more organ transplant e.g. Kidney and Pancreas).
  • Patient with high risk of rejection (eg. Patients with a PRA >50%, black patients and patients with 2nd transplant who lost their first graft within the first 6 months).
  • Evidence of infiltrate, cavitation, or consolidation on chest x-ray obtained during pre-study screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01601821

Locations
Iran, Islamic Republic of
Modarres Hospital
Tehran, Iran, Islamic Republic of
Shariati Hospital
Tehran, Iran, Islamic Republic of
Taleqani Hospital
Tehran, Iran, Islamic Republic of
Labbafinejad Hospital
Tehran, Iran, Islamic Republic of
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01601821     History of Changes
Other Study ID Numbers: 0468H-102012, B1741220
Study First Received: May 3, 2012
Results First Received: April 29, 2013
Last Updated: April 29, 2013
Health Authority: Iran: Ministry of Health

Additional relevant MeSH terms:
Inflammation
Pathologic Processes
Sirolimus
Everolimus
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 18, 2014